Smith & Wesson Brands, Inc. (SWBI)

NASDAQIndustrialsAerospace & DefenseSnapshot 2026-10-23

$13.71-4.46%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Smith & Wesson Brands, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-10-31
Revenue	—	136.48M
EPS	—	0.09
Annual ending 2027-04-30
Revenue	—	559.35M
EPS	—	0.59
Annual ending 2028-04-30
Revenue	—	571.89M
EPS	—	0.6

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Consistent dividend payments	A supporting condition in Smith & Wesson Brands, Inc.'s published investment case. The stated target is Dividend per share >= $0.13 per quarter through 2026-Q3.	Intact	Dividend per share falls below $0.13 in any quarter through 2026-Q3	Dividend per share: $0.13 per share FY2027-Q1; GAAP. Published target: Dividend per share >= $0.13 per quarter through 2026-Q3. The stored target says 2026-Q3; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Source published Sep 3, 20260.13 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jul 31, 2026 Source: company_financial_results. Reference: cdc8b313-2c6f-4408-9e0f-aedea3df5f1d. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 of 3 supplied transcript periods. The quarterly dividend remained $0.13 per share in 2026-Q3, when revenue was $112.587 million. The recurring dividend authorization is consistent with the stated policy, but the supplied data show no specific capital-allocation milestone this quarter, so delivery evidence is limited. Delivery assessment Oct 24, 2026
Operating income growth supports profitability and capital returns	Profit margins improve with operating income rising from $4.7M to $6.7M in recent quarters.	Intact	Operating income falls below $4.7M in 2026-Q3	Operating income: $4.217M FY2027-Q1; GAAP. Published target: Operating income >= $6.7M in 2026-Q3. The stored target says 2026-Q3; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Source published Sep 3, 20264,217,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jul 31, 2026 Source: company_financial_results. Reference: cdc8b313-2c6f-4408-9e0f-aedea3df5f1d. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 of 3 supplied transcript periods. The quarterly dividend remained $0.13 per share in 2026-Q3, when revenue was $112.587 million. The recurring dividend authorization is consistent with the stated policy, but the supplied data show no specific capital-allocation milestone this quarter, so delivery evidence is limited. Delivery assessment Oct 24, 2026
Revenue growth driven by healthy firearm demand	Smith & Wesson grows revenue about 14% yearly, driven by steady firearm demand.	Intact	YoY revenue growth falls below 10% in Q4 2026	Revenue growth: 0% FY2027-Q1; GAAP. Published target: >=10% YoY growth in Q4 2026 revenue. The stored target says 2026-Q4; this source reports FY2027-Q1. Fiscal/calendar alignment needs review. Source published Sep 3, 20260 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2027-Q1 · Period ending Jul 31, 2026 Source: company_financial_results. Reference: cdc8b313-2c6f-4408-9e0f-aedea3df5f1d. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-04-30 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-09-05	Unavailable	Unavailable	1 / 1
2026-09-06	Unavailable	Unavailable	1 / 1
2026-09-07	Unavailable	Unavailable	1 / 1
2026-09-08	Unavailable	Unavailable	1 / 1
2026-09-09	Unavailable	Unavailable	1 / 1
2026-09-10	Unavailable	Unavailable	1 / 1
2026-09-11	Unavailable	Unavailable	1 / 1
2026-09-12	Unavailable	Unavailable	1 / 1
2026-09-13	Unavailable	Unavailable	1 / 1
2026-09-14	Unavailable	Unavailable	1 / 1
2026-09-15	Unavailable	Unavailable	1 / 1
2026-09-16	Unavailable	Unavailable	1 / 1
2026-09-17	Unavailable	Unavailable	1 / 1
2026-09-18	Unavailable	Unavailable	1 / 1
2026-09-19	Unavailable	Unavailable	1 / 1
2026-09-20	Unavailable	Unavailable	1 / 1
2026-09-21	Unavailable	Unavailable	1 / 1
2026-09-22	Unavailable	Unavailable	1 / 1
2026-09-23	Unavailable	Unavailable	1 / 1
2026-09-24	Unavailable	Unavailable	1 / 1
2026-09-25	Unavailable	Unavailable	1 / 1
2026-09-26	Unavailable	Unavailable	1 / 1
2026-09-27	Unavailable	Unavailable	1 / 1
2026-09-28	Unavailable	Unavailable	1 / 1
2026-09-29	Unavailable	Unavailable	1 / 1
2026-09-30	Unavailable	Unavailable	1 / 1
2026-10-01	Unavailable	Unavailable	1 / 1
2026-10-02	Unavailable	Unavailable	1 / 1
2026-10-03	Unavailable	Unavailable	1 / 1
2026-10-04	Unavailable	Unavailable	1 / 1
2026-10-05	Unavailable	Unavailable	1 / 1
2026-10-06	Unavailable	Unavailable	1 / 1
2026-10-07	Unavailable	Unavailable	1 / 1
2026-10-08	Unavailable	Unavailable	1 / 1
2026-10-09	Unavailable	Unavailable	1 / 1
2026-10-10	Unavailable	Unavailable	1 / 1
2026-10-11	Unavailable	Unavailable	1 / 1
2026-10-12	Unavailable	Unavailable	1 / 1
2026-10-13	Unavailable	Unavailable	1 / 1
2026-10-14	Unavailable	Unavailable	1 / 1
2026-10-15	Unavailable	Unavailable	1 / 1
2026-10-16	Unavailable	Unavailable	1 / 1
2026-10-17	Unavailable	Unavailable	1 / 1
2026-10-18	Unavailable	Unavailable	1 / 1
2026-10-19	Unavailable	Unavailable	1 / 1
2026-10-20	Unavailable	Unavailable	1 / 1
2026-10-21	Unavailable	Unavailable	1 / 1
2026-10-22	Unavailable	Unavailable	1 / 1
2026-10-23	Unavailable	Unavailable	1 / 1
2026-10-24	Unavailable	Unavailable	1 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	2	0	0
2026-06-01	2	0	0
2026-07-01	2	0	0
2026-08-01	2	0	0
2026-09-01	2	0	0
2026-10-01	2	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Consistent dividend paymentsDividend per share: $0.13 per share
Operating income growth supports profitability and capital returnsOperating income: $4.217M
Revenue growth driven by healthy firearm demandRevenue growth: 0%

Next proof point

Dec 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.3%Typical daily move · historical

Downside history

-26.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Smith & Wesson Brands, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

SWBI is a product-driven industrial business with a fragile earnings profile, rather than a steady compounder. Its three-to-six-month thesis is intact because recent financial performance remains relatively strong, though company momentum has weakened and sector conditions are a headwind.

What's priced into Smith & Wesson Brands, Inc.

The evidence describes SWBI as expensive versus peers, even though one valuation signal points to it being cheap relative to peers. The overall priced-in tag is justified, with low fragility, so the evidence does not suggest that weak execution alone makes expectations unusually fragile.

What the fundamentals likely do

Near term, results may remain uneven: third-quarter sales were higher than a year earlier but lower than the prior quarter, and the fiscal 2027 revenue-growth outlook is not yet confirmed by those results. New products contributed 37.5% of fourth-quarter fiscal 2026 revenue, while the latest quarter does not isolate innovation’s effect; the next guidance update and the recent acquisition add uncertainty.

What Smith & Wesson Brands, Inc. hinges on

Over the next few quarters, the thesis hinges on delivering the stated fiscal 2027 growth outlook without a guidance cut. Strong results and guidance from the named industrial bellwethers could support the sector backdrop, while misses or lower guidance could remove that support. The acquisition’s effect and the equity-securities filing are not explained in the evidence, so their implications remain unclear.